Optimization of five-channel microfluidic device to study cell-to-cell communications in the tumor microenvironment
Abstract
Breast cancer is one of the most common and aggressive cancers in the world. About 30% of American Women get breast cancer, making it the second leading cause of cancer death. To study the progression of the cancer, scientists study the tumor microenvironment, which also drives drug resistance. To study these things within the TME, we use a 3D study platform, such as a microfluidic device, to study cell-to-cell communication via paracrine signaling. Transwell Assay is the standard for performing co-culture, but its limitations include being unable to capture images of cells or directly measure changes in the tumor secretome. Our goal was to create a new microfluidic device approach to study cell-to-cell communication in the TME to focus more closely on the cells. This novel approach will provide a more accurate view of the TME, potentially revealing new insights into breast cancer progression and drug resistance and ultimately contributing to the advancement of targeted and effective treatment strategies.
Optimization of five-channel microfluidic device to study cell-to-cell communications in the tumor microenvironment
TBD
Breast cancer is one of the most common and aggressive cancers in the world. About 30% of American Women get breast cancer, making it the second leading cause of cancer death. To study the progression of the cancer, scientists study the tumor microenvironment, which also drives drug resistance. To study these things within the TME, we use a 3D study platform, such as a microfluidic device, to study cell-to-cell communication via paracrine signaling. Transwell Assay is the standard for performing co-culture, but its limitations include being unable to capture images of cells or directly measure changes in the tumor secretome. Our goal was to create a new microfluidic device approach to study cell-to-cell communication in the TME to focus more closely on the cells. This novel approach will provide a more accurate view of the TME, potentially revealing new insights into breast cancer progression and drug resistance and ultimately contributing to the advancement of targeted and effective treatment strategies.
